BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share.

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

CARSON CITY, Nev., Oct. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share, resulting in total gross proceeds of $6,000,750, before deducting the placement agent's fees and offering expenses.

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Genetic Technologies

ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET).

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CARSON CITY, Nev., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of a previously announced best efforts public offering of 1,360,800 shares of its common stock, pre-funded warrants to purchase 600,000 shares of its common stock (“Pre-funded Warrants”) and warrants to purchase up to 1,960,800 shares of common stock (the "Common Warrants") at a combined public offering price of $1.53 per share (or Pre-funded Warrant) and associated Common Warrant. The Common Warrants have an exercise price of $1.53 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.

BioVie Inc. Announces Closing of Public Offering

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday.

Crude Oil Gains Over 1%; BioVie Shares Plunge

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions.

BioVie Inc. Announces Pricing of Public Offering

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying common stock purchase warrants in a best efforts public offering. All of the shares of common stock (and/or Pre-Funded Warrants) and accompanying common stock purchase warrants are to be sold by the Company.

BioVie Inc. Announces Proposed Public Offering

Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to receive bulk of $13.1 million grant funding

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim's impact on neurological symptoms associated with long COVID

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024 Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024

BioVie Inc. Announces Reverse Stock Split

bioAffinity Technologies Inc

ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET).

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mobilicom 

ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m.

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson's disease Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson's disease

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

CARSON CITY, Nev., June 12, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is pleased to invite investors to a webinar on June 26, 2024, at 4:15 p.m. ET.

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

BioVie Inc (NASDAQ:BIVI), a clinical-stage company focused on innovative drug therapies, announced today the approval of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD) to evaluate Bezisterim (NE3107) for treating neurological symptoms associated with long COVID.

BioVie secures $13.1M funding from US Department of Defense for Long COVID treatment

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with dementia, metabolism and inflammation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston from April 23 to 25. Additionally, the company said that bezisterim has been approved as the generic name for NE3107 by the United States Adopted Names Council and World Health Organization International Nonproprietary Names expert committee.

BioVie presents new data showing lead drug asset may promote healthier aging

CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston, Massachusetts April 23-25.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107 Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107

News for BioVie Inc Stock (BIVI)